You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Krystal Biotech reported $127.3 million in third-quarter VYJUVEK revenue and $63.1 million in net income, ended September 30, 2026 with $1.2 billion in cash and investments, and authorized a share repurchase program of up to $400 million.
Krystal Biotech reported VYJUVEK product revenue, net of $127.3 million for the three months ended September 30, 2026, versus $97.8 million, with a 94% gross margin. Nine-month product revenue, net was $362.9 million, and cumulative revenue since 2023 reached $1,093.3 million.
Krystal Biotech reported that KB113 regressed over 80% of assessed basal cell carcinoma lesions in three Gorlin syndrome patients, with 83.1% overall regression, and was generally well tolerated. The company is discussing advanced clinical development with the FDA.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Krystal Biotech reported Q2 2026 global VYJUVEK revenue of $119.2 million (up 24% year-over-year), with 95% gross margin, $54.8 million in net income, and over $1.1 billion in cash. Reimbursement approvals in the U.S. surpassed 730 and the prescriber base expanded to over 640, while European launches continued with pricing discussions ongoing in Germany and France and launches in Italy and Spain expected before year-end. The clinical pipeline advanced with multiple registrational readouts slated for 2H 2026 and additional registrational study starts planned for 2027.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and investments | 1.1B | as of June 30, 2026 | — |
| Disease control rate (KB707 plus pembrolizumab, NSCLC) | 75% | KYANITE-1 interim results presented May 2026 | — |
| Gross margin | 95% | the three months ended June 30, 2026 filing | — |
| Objective response rate (KB707 plus pembrolizumab, NSCLC) | 31% | KYANITE-1 interim results presented May 2026 | — |
| Reimbursement approvals | 730 | as of the end of 2Q 2026 | — |
| Unique prescribers | 640 | as of the end of 2Q 2026 | — |
| VYJUVEK cumulative net product revenue since launch | $965.9M | since launch | — |
| VYJUVEK global net product revenue | $119.2M | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KRYS
this stock
Krystal Biotech, Inc.
|
$9.05B | +23.8% | +33.9% | 41.5 | 10.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Krystal Biotech reported $127.3 million in third-quarter VYJUVEK revenue and $63.1 million in net income, ended September 30, 2026 with $1.2 billion in cash and investments, and authorized a share repurchase program of up to $400 million.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KRYS | +1.5% | -3.6% | +0.8% | -8.1% | +23.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.1% | -2.4% | +0.3% | -8.0% | +13.2% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
